- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05239143
Células CAR-T alogénicas P-MUC1C-ALLO1 en el tratamiento de sujetos con tumores sólidos avanzados o metastásicos
Un estudio de fase 1 de escalamiento de dosis y cohorte ampliada de P-MUC1C-ALLO1 en sujetos adultos con tumores sólidos avanzados o metastásicos
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is an open label, multi-center Phase 1 study that will follow a 3 + 3 design of dose-escalating cohorts of single and multiple doses of P-MUC1C-ALLO1 to determine a Recommended Phase 2 Dose (RP2D). P-MUC1C-ALLO1 is an allogeneic chimeric antigen receptor (CAR) T cell therapy designed to target cancer cells expressing Mucin1 cell surface associated C-Terminal (MUC1-C) antigen. Additional participants will be treated with P-MUC1C-ALLO1 at the determined RP2D.
Following enrollment, subjects will be treated with P-MUC1C-ALLO1 and will undergo serial measurements of safety, tolerability and response. Rimiducid may be administered as indicated.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
Irvine, California, Estados Unidos, 92868
- University of California, Irvine Medical Center
-
Los Angeles, California, Estados Unidos, 90048
- Cedars Sinai Medical Center
-
San Diego, California, Estados Unidos, 92037
- University of California, San Diego
-
San Francisco, California, Estados Unidos, 94143
- University of California, San Francisco
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80218
- Sarah Cannon Research Institute at HealthONE
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- University of Iowa Hospitals and Clinics
-
-
Kansas
-
Westwood, Kansas, Estados Unidos, 66205
- University of Kansas Cancer Center
-
Wichita, Kansas, Estados Unidos, 67214
- Cancer Center of Kansas
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21201
- University of Maryland Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Dana Farber Cancer Institute
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68198
- University of Nebraska Medical Center
-
-
New York
-
The Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- MD Anderson Cancer Center
-
San Antonio, Texas, Estados Unidos, 78229
- NEXT Oncology
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Males or females, Subjects ≥18 years with life expectancy >3 months
- Must have a confirmed diagnosis of unresectable, locally advanced or metastatic epithelial-derived cancer
- Must have progressed during or after last therapy, developed intolerance/toxicity to current treatment, or ineligible or refused other existing treatment options, and have measurable disease
- Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 or Karnofsky performance status ≥70%
- Must have adequate vital organ function within pre-determined parameters
- Must have archived tumor tissue available or consent to a biopsy collection
- Must be willing to practice birth control
- Must have a negative pregnancy test at screening and prior to initiating lymphodepletion chemotherapy or study drug administration
- Must have recovered from toxicities due to prior therapies
Exclusion Criteria:
- Has inadequate venous access
- Has an active second malignancy (not disease free for at least 5 years) in addition to the studied malignancy, excluding low-risk neoplasms such as non-metastatic basal cell or squamous cell skin carcinoma
- Is pregnant or lactating
- Has a history of or active autoimmune disease
- Has a history of significant central nervous system (CNS) disease, such as stroke, epilepsy
- Has an active systemic (viral, bacterial, or fungal) infection
- Has New York Heart Association (NYHA) Class III or IV heart failure, unstable angina, or a history of myocardial infarction or significant arrhythmia
- Has any psychiatric or medical disorder that would preclude safe participation in and/or adherence to the protocol
- Has received anticancer medications within 2 weeks of the time of initiating lymphodepletion
- Has received immunosuppressive medications within 2 weeks of administration of P-MUC1C-ALLO1, and/or expected to require them while enrolled in the study
- Has received systemic corticosteroid therapy within 1 week of the administration of P-MUC1C-ALLO1 or is expected to require it during the course of the study
- Has known CNS metastases or symptomatic CNS involvement
- Has a history of significant liver disease or active liver disease
- Has a history of known genetic predisposition to HLH/MAS
- Has received anti-cancer monoclonal antibody therapy within 4 weeks of initiating LD therapy
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
|
Experimental: P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm B)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
|
Experimental: P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm C)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
|
Experimental: P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm D)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
|
Experimental: P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A1)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
|
Experimental: P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm E)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
|
Experimental: P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm F)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
|
Experimental: P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm M)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of P-MUC1C-ALLO1
Periodo de tiempo: Baseline through Day 28
|
Number of subjects with a dose limiting toxicity (DLT) |
Baseline through Day 28
|
|
Evaluate the overall safety and tolerability profile of P-MUC1C-ALLO1
Periodo de tiempo: Baseline through 15 years
|
Frequency and severity of adverse events |
Baseline through 15 years
|
|
Evaluate the preliminary efficacy of P-MUC1C-ALLO1
Periodo de tiempo: Baseline through 15 years
|
According to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, secondarily Immune Response Evaluation Criteria in Solid Tumors (iRECIST): Overall Response Rate (ORR) |
Baseline through 15 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Simon Heidegger, M.D., Lead Medical Director, Oncology, Genentech Research Early Development
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Enfermedades del sistema endocrino
- Enfermedades Estomatognáticas
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades urogenitales masculinas
- Enfermedades Renales
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades intestinales
- Enfermedades de las vías respiratorias
- Neoplasias por tipo histológico
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades del Sistema Digestivo
- Enfermedades Gastrointestinales
- Enfermedades del Estómago
- Neoplasias Intestinales
- Enfermedades Rectales
- Enfermedades Genitales Femeninas
- Enfermedades pulmonares
- Neoplasias de glándulas endocrinas
- Neoplasias de Cabeza y Cuello
- Enfermedades pancreáticas
- Neoplasias Glandulares y Epiteliales
- Adenocarcinoma
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Enfermedades del Colon
- Neoplasias Pulmonares
- Enfermedades Ováricas
- Enfermedades anexiales
- Neoplasias Genitales Femeninas
- Trastornos gonadales
- Enfermedades de la piel
- Enfermedades de los senos
- Neoplasias Urológicas
- Carcinoma
- Enfermedades Otorrinolaringológicas
- Neoplasias Renales
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Neoplasias faríngeas
- Neoplasias Otorrinolaringológicas
- Enfermedades Nasofaríngeas
- Enfermedades faríngeas
- Carcinoma De Células Escamosas
- Enfermedades de la piel y del tejido conectivo
- Carcinoma de células escamosas de cabeza y cuello
- Neoplasias de Estómago
- Neoplasias colorrectales
- Neoplasias Ováricas
- Neoplasias de mama
- Neoplasias pancreáticas
- Carcinoma De Célula Renal
- Carcinoma de pulmón de células no pequeñas
- Neoplasias Nasofaríngeas
Otros números de identificación del estudio
- P-MUC1C-ALLO1-001
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .